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Behc ¸et’s disease is a multisystemic inﬂammatory disease of unknown etiology which usually occurs as a trait of symptoms:
aphthous stomatitis, genital ulcerations, and ocular disease. At the beginning of the disease the diagnosis is uncertain because
of various clinical manifestations and a long period up to the full clinical picture manifestation. Since neither the laboratory
data nor the histopathological signs are truly pathognomonic in Behc ¸et’s disease, the diﬀerential diagnosis depends on a careful
evaluationofthemedicalhistoryandmeticulousphysicalexaminationtodetectconcomitantsystemicmanifestations.Sometimes,
some laboratory test may help establish the diagnosis. Subspecialty referral to ophthalmology, rheumatology, neurology, and
gastroenterology should be considered when indicated.
1.Introduction
Behc ¸et’s disease (BD) is a multisystemic inﬂammatory proc-
ess of unknown etiology, characterized by relapsing episodes
of oral aphthous ulcers, genital ulcers, other skin lesions,
and ocular lesions. The Turkish dermatologist Hulusi Behc ¸et
ﬁrst described the disease in 1937, as the triad of recurrent
oral aphthous ulcers, genital ulcers, and uveitis [1]. It can
aﬀect nearly every system and organ including ocular,
cardiovascular, gastrointestinal, renal, pulmonary, urologic,
and central nervous systems and the joints [1–4].
Itaﬀectspeoplemainlybetweentheagesof20to40.Both
genders are usually equally aﬀected [2, 3]. However diﬀerent
male-to-female ratio was recorded in some countries: there
is a male predominance in Middle Eastern countries, such
as Iraq, Jordan, Saudi Arabia, and Lebanon, while a female
predominance is seen in the USA and Britain [4–8].
Because there are no speciﬁc diagnostic laboratory tests
or histopathologic ﬁndings, the diagnosis of the disease relies
on clinical criteria and often takes several years to establish
a deﬁnitive diagnosis after the appearance of the initial
manifestations. Manifestations of BD are not consistent
among patients. Clinical phenotypes are very heterogeneous
and evolution of the disease vary due to ethnic, geographical,
and individual diﬀerences.
Moreover,theinitialmanifestationsandthecombination
of clinical symptoms are very heterogeneous from patient to
patient, even within the same ethnic group. Some patients
present with only mucocutaneous symptoms, while some
suﬀer from systemic involvement causing serious complica-
tions.
As there are no pathognomonic clinical ﬁndings, various
diagnostic criteria and classiﬁcations have been proposed
during the years. According to criteria of International
Study Group which was proposed in 1990, the presence of
oral aphthous ulcerations and two of the following clinical
manifestations is required for the diagnosis of BD: recurrent
genital ulcerations, skin lesions such as erythema Nodosum-
Likelesions,papulopustularlesions,ocularinvolvement,and
positive pathergy test [9]( Table 1).
The most common presenting symptoms of the dis-
ease are mucocutaneous features [10–12]. Recurrent oral
aphthous ulcerations and genital ulcerations are the most
common.
Other skin lesions, such as erythema Nodosum-Like
lesions,papulopustularlesions,superﬁcialthrombophlebitis,
pathergy reaction, pyoderma gangrenosum-like lesions,
Sweet’s syndrome-like lesions, and erythema multiforme can
be observed in about 80% of the patients with BD [2, 10,
11, 13]. In addition, extragenital ulcers, palpable purpura,2 Pathology Research International
Table 1: International Study Group criteria for the diagnosis of
Behc ¸et’s disease [9].
Recurrent oral ulceration
Minor/major aphthous or herpetiform
ulcer observed by the physician or
patient which recurred at least three
times in one 12-month period
Plus two of the following:
Recurrent genital
ulceration
Aphthous ulcer or scarring observed
by the physician or patient
Eye lesions
Anterior/posterior uveitis, cells in the
vitreous on slit-lamp examination or
retinal vasculitis observed by an
ophthalmologist
Cutaneous lesions
Erythema nodosum observed by
physician or patient, pseudofolliculitis
or papulopustular lesions, or
acneiform nodules observed by
physician in postadolescent patients
not receiving corticosteroids
Positive pathergy test Interpreted by the physician at 24–48h
hemorrhagic bullae, furuncles, abscesses, perniolike lesions,
and subungual infarctions, can also be seen less commonly
in BD [2, 11].
Prognosis depends on the clinical involvement and the
disease may result in considerable morbidity and mortality.
Loss of visual acuity and neurological disease are major
causes of morbidity and disability. Involvement of nervous,
gastrointestinal, and large vascular systems may be lethal or
can leave irreversible deﬁcits.
Severe clinical course and systemic involvement are
observedwhenearlyonsetofthediseaseispresent[2,11,14].
Male sex and HLA B51 positivity are also associated with
more severe disease [2, 10, 11].
Diseasecourseusuallygetsbetterwiththepassageoftime
with decrease in mortality rate.
2. MucocutaneousManifestationsof
Behc ¸et’sDisease
2.1. Recurrent Oral Aphthous Ulcers. Recurrent oral aph-
thous ulcers (ROAUs) are a sine qua non future of BD
according to the International Study Group criteria [9].
Oral aphthous ulcers frequently the ﬁrst manifestation
of BD recurring at least 3 times a year. It characteristically
precede by many years the onset of other manifestations.
They may be single or multiple and can occur after local
trauma and dental intervention. The ulcer covered with
grayish-white pseudo membrane or central necrotic base
with round and sharp erythematous border is termed as
punched-out ulcer. The ulcers are usually so painful that
the patient is unable to eat during the attack. However,
some patients with BD may paradoxically report no painful
symptoms during active disease, despite the existence of
extensive oral ulceration. The most commonly involved sites
of ulcers are gingival, buccal and labial mucosa, and tongue
Table 2:Systemicconditionspresentingwithaphthous-likelesions.
Behc ¸et’s disease
Gastrointestinal disorders
Nutritional/Heamatological deﬁciencies
Heamatological diseases
MAGIC syndrome
Reiter syndrome
PFAPA syndrome
Sarkoidoz
Drug reactions
although they can also appear in the soft and hard palate,
oropharynx, and tonsils [12, 15, 16].
Minor ulcers (<1cm in diameter) are the most (80%–
85%) common form of ROAU. They are shallow, small
ulcers,1–5innumbers,moderatelypainful,andhealwithout
scarring in 4–14 days [10, 17]. Major ulcers, less common
form, may be more painful and heal with scarring in 2–
6 week. Herpetiform ulcers, the least common form, are
numerous small (2-3mm) and painful ulcers which may
become coalescent. Uncommonly, patients may present with
a mixed pattern.
ROAU of BD should be diﬀerentiated from those of re-
current oral ulcers due to other causes.
The common causes of oral ulcer are trauma, recur-
rent aphthous stomatitis (RAS), infections (herpes sim-
plex, syphilis, HIV, herpangina, primer herpetic gingivos-
tomatitis, and hand-foot-mouth disease), mucocutaneous
disease (lichen planus, erythema multiforme), immunobul-
lous disease (pemphigus), squamous cell carcinoma, cyclic
neutropenia, drugs, and systemic disorders [12, 16, 18].
Systemic conditions presenting with “aphthous-like” lesions,
including BD, have been shown in Table 2:o ra lu l c e r sm a ybe
a part of systemic lupus erythematosus, MAGIC syndrome,
Reiter’s syndrome, and Sweet’s syndrome, or may be sec-
ondary to hematinic/nutritional deﬁciencies (iron, vitamin
and B12, folic acid, Coeliac disease) and heamatological
diseases (cyclic neutropenia, lymphoma) [12, 15]. The ulcers
of oral mucosa can be seen in inﬂammatory bowel disease,
especially in Crohn’s disease and, to a lesser extent, in
ulcerative colitis.
In addition to a complete anamnesis and detailed review
of systems, some laboratory tests such as Tzanck smear,
polymerase-chain-reaction-based (PCR) assays, complete
blod count, determination of serum B12, folate, and iron
levels, and sometimes histopathologic examination may help
diagnosis in cases with such lesions.
In some situation, the clinical presentation of the oral
ulcers of some diseases is diﬀerent from that of ROAU of
BD, like those in systemic lupus erythematosus: oral ulcers
seeninthisdiseasehaveirregularandslitlikeappearance.The
lesions tend to occur on the palate and often heal with a scar.
Similarly, mucocutaneous lesions of Reiter’s syndrome may
include red patches or superﬁcial painless mucosal erosions.
Theulcersintheinﬂammatoryboweldiseasesaremorelikely
to manifest as other types of oral ulceration. In Crohn’sPathology Research International 3
disease, the oral lesion are deep ﬁssures, and they appear as
linear ulcers.
However oral ulcers, which due to other causes, are
usually indistinguishable clinically from the ROAU of BD
like those in RAS. RAS is a common oral mucosal condition,
characterized by recurrent bouts of one or several shallow,
rounded, or ovoid, painful ulcers, that recur at intervals of
a few days or up to 2-3 months [16]. The minor aphthous
lesions of RAS, which are most common form, often occur
in the anterior part of the mouth though they can be seen
at any site of oral mucosa. Although ROAU of BD cannot be
distinguished clinically from common ulcers of RAS, clinical
observation suggest that patients with BD tend to have more
ulcers with more frequent crops, more painful and wider,
and longer duration than those with RAS [18]. The patients
with BD are more frequently presented with major aphthae
than the patients with RAS [19] .R O A U si nB Da p p e a rt o
be associated with increased tissue oedema and to have an
intensely erythematous border. In addition, involvement of
the soft palate and oropharynx is more common in BD than
in RAS [10, 17, 18].
Most patients with RAS will not develop associated
disease. However, because ROAUs of BD are the most
common presenting manifestation and may precede the
diagnosis of BD by 6-7 years as the only manifestation,
the diﬀerential diagnosis of BD must be considered in the
case of any new clinical problem appear in patients with
RAS. Similarly, patients with complex aphthosis also must
be monitored at intervals using clinical criteria for evolution
into BD. Complex aphthosis is the term used to describe
the patients who have constant presence of multiple oral
ulcers, or recurrent oral and genital ulcers, without systemic
manifestations of BD.
Histopathologic examination of oral ulcers in BD has a
nonspeciﬁc pathology with a variable inﬁltrate of lympho-
cytes, macrophages, and neutrophils at the base of the ulcer.
Leukocytoclastic and lymphocytic vasculitis may be seen if
the inﬂammation is severe [20].
Reimer et al. showed that there are no diﬀerence between
direct IF on oral aphthae in RAS compared to BD [21].
Theyfoundthat,comparedtononaphthousorallesions,oral
aphthae of BD and RAS are characterized by C3 deposition
in the vessel walls. IgM deposits also were detected in vessel
w a l l si ns o m ep a t i e n t si nb o t hg r o u p s .
2.2. Genital Ulcers. Genital ulcers (GU) are the second most
commonly observed initial manifestation in BD which occur
in about 80–90% of patients. They resemble oral aphthous
ulcerationsbutarelargeranddeeperandhavemoreirregular
border [12, 13, 22, 23]. GU frequently heal by scarring.
They occur usually on the scrotum in males and on the
vulva in females, which are most common in labia. In males,
the shaft and glans penis may also be aﬀected. Perineal,
perianal, and groin lesions can occur in both sexes [10].
In females, vaginal and cervical lesions may be seen and
may be associated with vaginal discharge. GU tend to be
larger and deeper in female patients and sometimes lead
to perforations. Large GU, frequently leave a scar, whereas
small ulcers, especially those on the minor labia may heal
without leaving a mark [2, 10, 11, 24]. Because ulcers
are occasionally asymptomatic, patient assessment should
include examination of genitalia for ulcersand scarring, even
when symptoms are absent.
Histopathologic feature of GU of BD similar to that of
ROAU.
Genital ulcerations should be diﬀerentiated from vene-
real diseases such as syphilis, chancroid, and herpes simplex
virus infection. Fix drug eruption, erythema multiforme,
erosive lichen planus, otoimmun bullous dermatoses must
be considered in the diﬀerential diagnosis. Recurrent genital
ulcerations may also be seen in Munchausen syndrome,
hypereosinophilic syndrome, myelodysplastic syndrome,
tuberculosis cutis, and acquired immune deﬁciency syn-
drome [3, 4, 11].
2.3. Papulopustular Lesions. Papulopustular lesions or acne-
like lesions may appear at any location and they are mor-
phologically similar to adolescent acne. They are (28–
96%) the most common cutaneous manifestation, and
their distribution is more widespread than adolescent acne,
aﬀecting face, limbs, trunk, and buttocks [15, 22]. Diri et al.
showed that papulopustular lesions are seen more frequently
in patients with BD with arthritis [25].
ThepapulopustularlesionsofBehc ¸et’sdiseasearelocated
more often on the lower part of the body, while the lesions
of adolescent acne are seen more frequently on the upper
part. In addition, the pathogenesis of papulopustular lesions
of Behc ¸et’s disease is diﬀerent from those of acne vulgaris.
According to some authors, papulopustular lesions of BD are
a vasculitis, while acne vulgaris is a sebaceous gland disorder
under hormonal factors. On the other hand, a controversy
exists as to the histopathologic features of papulopustular
lesions [12, 26–29]. These lesions are generally nonspeciﬁc
also histopathologically as well as being clinically accord-
ing to some authors. They advised that follicular lesions,
showing suppurative folliculitis or perifollicular inﬁltration
should be excluded, and only lesions with vessel-based and
neutrophilic histologic ﬁndings should be considered as
papulopustular lesions of BD [27].
Alpsoy et al. pointed out that the detection of nonfol-
licular lesions over the trunk or extremities, with the sup-
port of histopathologic and/or immunoﬂuorescence studies,
increases the speciﬁcity of these lesions [26]. Papulopustular
lesions were included in the International Study Group Cri-
teria as a result of their 70% sensitivity and 76% speciﬁcity;
whereas some authors stated that papulopustular lesions
exhibiting vessel-based neutrophilic reaction and follicle-
based lesions are both features of Behc ¸et’s disease, and
any papulopustular lesions, including follicular acneiform
lesions, should be regarded as features of Behc ¸et’s disease
[12, 28]. Boyvat considering this argument, pointed out that
papulopustularlesionsofBDwhichhavenonspeciﬁcfeatures
may create problems in the diagnosis of Behc ¸et’s disease
because they are extremely common also in the general
population [12].
2.4. Erythema Nodosum-Like Lesions. The prevalence of er-
ythema Nodosum-Like lesions was reported as 15–78% with4 Pathology Research International
a higher frequency in females [2, 11, 16, 30]. The lesions are
tender erythematous nodules predominantly aﬀect the lower
limbs, although they can also appear at other sites, including
the upper extremities, buttocks, and less commonly on the
face and neck [2, 11, 15]. Often, they have more erythema
and edema around the lesions than the classic erythema
nodosum [31]. The lesions do not ulcer. They heal within
a few weeks and usually leave a hyperpigmentation after
healing [10, 15]. Recurrence is common.
Histopathological ﬁndings of erythema Nodosum-Like
lesions have been reported as leukocytoclastic vasculitis,
neutrophilic vascular reaction, lymphocytic vasculitis, lym-
phohistiocytic septal/lobular panniculitis, granulomatous
panniculitis, or acute necrotizing panniculitis [30, 32, 33]. In
a study, evaluating histopathological features of the nodular
lesions of BD and erythema nodosum associated with other
systemic diseases, it has been found that septal panniculitis,
lymphocyte-predominatinginﬁltrateinthesubcutis,absence
of vasculitis, and necrosis were in favor of erythema
nodosum, while neutrophil-predominated inﬁltrate in the
s u b c u t i sw a sm o r ec o m m e ni nB D[ 34]. Some authors
have emphasized that early lesions show a leukocytoclastic
vasculitis or a neutrophilic vascular reaction, whereas older
lesions have a lymphocytic vasculitis [10, 15, 26, 27].
2.5. Superﬁcial Thrombophlebitis. Superﬁcial phlebitis,
which is one of the characteristics of BD, appears as painful
subcutaneous nodule or stringlike hardening with reddening
of the overlying skin, predominantly located on the lower
extremities [2, 35]. It is segmental and can present in a
characteristic migratory pattern. Although it is transient,
which disappears in a few days, it has a tendency to recure.
Superﬁcial thrombophlebitis has been reported to be present
in 2.2–20% of Behc ¸et patients with higher prevalence in
males [2, 10, 11]. Vena saphena magna is the most aﬀected
vein.
It can be diﬀerentiated from erythema Nodosum-Like
lesions, which may be similar clinically, by dermal ul-
trasonography [36]: erythema Nodosum-Like lesions are
hyperechoic on sonography, while the lesions of superﬁcial
thrombophlebitis are hypoechoic.
It is important that, because of the relationship between
superﬁcial thrombophlebitis and deep venous thrombosis,
closemonitoringisrequiredforthevascularsystemicdisease.
On histopathologic examination, organized thrombus is
observed in the vein lumen. Fibrous thickening of the vein
wall and sometimes inﬁltration of mononuclear cells may be
seen [12].
2.6. Pathergy Test. Pathergy is the term used to describe
hyperreactivity of the skin that occurs in response to any
intracutaneous injection or needle prick, characterized by
the formation of a sterile pustule or erythematous small
papule after 24–48 hours [11]. In addition to skin pathergy
test, some authors described oral pathergy test [37, 38]. The
test is more strongly positive in male patients than in female
[2, 39, 40].
Pathergy test is usually positive at the active phase of BD,
though positivity is not associated with disease severity and
the age of onset of BD [41]. Positivity of the test varies with
geographical location: in the Mediterranean and Middle/Far
Eastern countries, there is a high-pathergy positivity (40–
98%) [2, 10, 11, 30]. While a positive pathergy test is
an important parameter in the diagnosis of BD in these
countries, the diagnostic value of the test is limited by its low
sensitivity in Western countries [42, 43].
There are controversies about the histopathology of the
pathergy reaction. Some authors found mixed inﬁltration,
while others reported neutrophilic inﬁltration with leukocy-
toclastic vasculitis [40, 44].
2.7. Extracutaneous Ulcers. Extracutaneous ulcers are un-
common (3%). They are 20 to 30mm in diameter with a
y e l l o w i s hn e c r o t i cb a s e .T h eu l c e r sa r er e c u r r e n ta n do c c u r
mainly on the internal part of the thighs, in the inguinal
and axillary regions, but can aﬀect neck, inframammary and
perianal areas, breast, legs, and interdigital area of the feet
[2, 10, 12, 15]. Extragenital ulcers look like aphthous ulcers
and commonly heal leaving a round atrophic scar. They are
common in children with Behc ¸et’s disease [10, 45]. In some
cases, vasculitis had been described [45].
2.8. Sweet’s Syndrome-Like Lesions. Sweet’s syndrome-like
lesions are rarely seen in patients with Behc ¸et disease and,
if present, are usually fewer in number [46]. They are seen as
painful erythematous nodules and plaques, associated with
fever and leucocytosis. Sometimes, they may be pustular.
SweetSyndromelikelesionscanbeseenontheface,neck,and
extremities.
The lesions demonstrate neutrophilic inﬁltration, or per-
ivascular and periadnexal inﬂammatory inﬁltrate of lym-
phocytes, histiocytes, and neutrophils in the dermis. In some
cases, vasculitis may also be seen [30, 46–48].
3. Systemic Involvement in Behc ¸etDisease
3.1. Ocular Involvement. Ocular involvement in BD is fre-
quent (28.9–80%) and is an important cause of morbidity
[49]. The highest prevalence rate of the disease has been
reported from Turkey and Japan [3, 4, 14]. The disease is
more frequent in males than females, and males tend to have
a worse visual prognosis [2, 11]. The mean age at onset of
uveitis is between 20 and 30 years in male and 30 years in
female patients [50].
Ocular manifestations are usually bilateral and typically
occur 2 or 3 years after the onset of the disease. It may be the
presenting manifestation of the disease in 10–20% of cases
[4, 50].
It was shown that the delay between the ﬁrst mani-
festation and eye involvement may be as long as 14 years
[51]. Ocular involvement carries a poor visual prognosis
despite therapeutic intervention [4, 50]. The estimated risk
of blindness at 5 years ranges from 15 to 25% [50].
The characteristic ocular feature is relapsing uveitis
as anterior, posterior, or panuveitis, and retinal vasculitis.
Anterior uveitis is frequently observed in females, whereas
panuveitis is commonly encountered in males [4, 52].Pathology Research International 5
Anterior uveitis with hypopyon, which has the picture of
inﬂammatory white exudate forming a visible layer of cells
in the anterior chamber is a characteristic sign of ocular BD.
Hypopyon is observed only in about one-third of patients
because it is transient [15, 42]. It usually disappears before
the patient is seen by the physician.
The typical ocular involvement has a course with attack
and remission. A single attack usually cures spontaneously
without producing any sequela. When attacks become
successive, they may produce sequela. The remission usually
occurs so slowly that before the lesion improves, a new
attack recurs which leads to severe sequelae such as synechia,
cataract, and less frequently glaucoma. Successive attacks
can also produce iris atrophy, atrophic retina, optic atrophy,
macular degeneration, retinal veins occlusion, optic neuritis,
phytisis bulbi, and loss of vision or blindness [4, 50, 53–
55]. Other ocular manifestations in BD include iridocyclitis,
keratitis, scleritis, episcleritis, vitritis, vitreous haemorrhage,
retinal neovascularization, optic neuritis, and chorioretinal
scars. However, conjunctivitis are not considered a usual
feature of BD. Posterior uveitis and retinal vasculitis are the
main causes for the loss of vision.
Clinical symptoms and signs include hyperemia, blurred
vision, photophobia, lacrimation, ﬂoaters, periorbital, or
global pain [4].
Intraocular inﬂammation associated with BD should be
diﬀerentiated from other infectious or noninfectious causes.
Uveitis may occur as a result of many conditions. A variety
ofinfectiousdiseasesincludingtoxoplasmosis,herpesviruses,
syphilis, tuberculosis, Lyme disease, cat scratch disease, and
Whipple’s disease must be ruled out by appropriate testing
[4]. Development of PCR-based assays and safer methods
for sampling of ocular ﬂuids have increased the ability
to diagnose infectious causes of uveitis. One of the most
diﬃcult diﬀerential diagnosis of BD is viral retinitis with
anterior segment involvement. The intraocular ﬂuids should
be subjected to culture, PCR, and immunohistochemical
tests for the detection of a possible viral etiology. Serologic
tests for syphilis and a chest radiograph which is a useful
screen for tuberculosis (and also for sarcoidosis) may be
useful.
Uveitismayoccurinthecontextofavarietyofinﬂamma-
tory diseases, including inﬂammatory bowel disease, Vogt-
Koyanagi-Harada syndrome, and multiple sclerosis. Other
causes of uveitis are intraocular tumors, in particular,
intraocular lymphoma and reactions to medications such
as cidofovir and rifabutin. Anterior uveitis and iridocyclitis
in BD should also be diﬀerentiated from idiopathic uveitis,
ankylosing spondylitis, Reiter syndrome, tubulointerstitial
nephritis, Kawasaki disease, and sarcoidosis [4, 54].
The diﬀerential diagnosis further includes speciﬁc ocular
inﬂammatory conditions, including Fuchs heterochromic
iridocyclitis characterized by unilateral anterior uveitis with
diagnostic corneal and iris changes; the “white dot syn-
dromes” which are characterized by round white lesions
involving choroid and/or retina and pars planitis character-
ized by a “snow bank” of inﬂammatory debris on the inferior
pars plana.
3.2. Neurological Involvement. Neurological involvement
occurs in 5–10% of patients in BD. It is an important
manifestation of BD because of its severe morbidity and
increasedmortality.Itusuallyappearswithin5yearsafterthe
onsetofthediseaseandismorefrequentinmen.Centralner-
vous system is more frequently involved than the peripheral
nervous system [56, 57]. There are two types of neurological
involvement: parenchymal and Nonparenchymal.
Parenchymal brain disease is more common (approx-
imately 80%) in BD, which mainly aﬀects the brainstem
and/or basal ganglia but spinal cord lesions and hemisphere
lesions may also occur. The classic manifestation is a
meningoencephalitis.
All forms of neurologic manifestations have been re-
ported in the patients with BD including headache, seizures,
brainstem syndromes, cerebellar syndromes, diencephalic
dysfunction, benign intracranial hypertension, ataxia, apha-
sia, pseudobulbar palsy, cranial nerve palsies, hemiplegia,
myelopathy, and mononeuritis multiplex. Cerebellar and
sensory symptoms and signs, sphincter disturbances, and
behavioural changes may also be observed. Among them,
pyramidal tract signs are the most frequently observed
manifestations [58–60].
Some of the symptoms such as stroke, epilepsy, brain
tumor, movement disorder, acute meningeal syndrome, and
optic neuropathy may also be seen less commonly.
Nonparenchymal disease includes dural sinus thrombo-
sis, arterial vasculitis, and aseptic meningitis [56]. Venous
sinus thrombosis is the most frequent vascular manifestation
in Nonparenchymal disease followed by cortical cerebral
veins thrombosis. Other vascular manifestations include
intracranial and extracranial aneurysm. In most cases, veins
a r em u c hm o r el i k e l yt ob ea ﬀected than arteries.
The most common neurologic symptom among patients
with Nonparenchymal disease is headache which is caused
by intracranial hypertension due to dural sinus thrombosis.
Cerebral venous thrombosis may result in stroke. Stroke-like
symptoms such as confusion, weakness, and dizziness may
also occur.
Dural sinus thrombosis has a relatively benign prognosis
in comparison to parenchymal involvement [3, 58, 59].
Involvement of parenchyma and a high protein or cell count
in cerebrospinal ﬂuid examination imply a worse prognosis
in BD [15].
The diﬀerential diagnosis of neurological involvement of
BD may include many diseases of the central nervous system.
One of them is multiple sclerosis. Although MRI ﬁndings
are distinctive in typical neurological involvement, when the
predominantlesionisintheperiventricularwhitematter,itis
diﬃculttodiscriminatefromthelesionsofmultiplesclerosis.
Other than multiple sclerosis, central nervous system
infection (especially when there are cerebrospinal ﬂuid pleo-
cytosis and fever), cerebrovascular disease, brain tumours,
and compressive myelopathy should be considered in the
diﬀerential diagnosis of neuro-Behc ¸et’s disease.
Neurologic involvement of BD disease must be consid-
ered in the diﬀerential diagnosis of stroke in young adults,
movement disorders, intracranial sinovenous occlusive dis-
eases and intracranial hypertension, and other neurologic6 Pathology Research International
syndromes. Imaging studies and/or cerebrospinal ﬂuid anal-
ysis may be helpful in some cases [61–63]. MRI diﬀerentiates
parenchymal lesions from the Nonparenchymal forms [63].
Diﬀusion-weighted imaging may be useful in the case of
stroke-like episodes, revealing an increase in the diﬀusion
coeﬃcient in BD lesions. The clinical similarity between
successive attacks may also be helpful for diagnosing BD.
Cerebrospinal ﬂuid glucose determination may be a useful
parameter to diﬀerentiate central nervous system involve-
ment in BD from other diseases, particularly infections [63,
64].
Histopathological studies, investigating central nervous
system involvement, have mainly demonstrated that there is
a perivascular lymphocytic inﬁltration with areas of necrosis
in BD [64–67]. It is uncertain whether the areas of necrosis
arecausedbyvasculitisorinﬂammatoryinﬁltratearoundthe
small vessels.
Riera-Mestre et al. have found perivascular lymphocytic
inﬁltration with reactive astrocytosis, but no frank vasculitis
in the brain biopsy specimens in their study [64]. They
suggestthattheabsenceofendothelialdegenerationsupports
a perivascular inﬂammatory process rather than frank vas-
culitis.
3.3. Gastrointestinal Involvement. The frequency of gastroin-
testinal system involvement is variable in diﬀerent countries
[4,15].InJapanandKorea,the prevalenceofgastrointestinal
system involvement is higher (15–45%) than that in the
Middle East and Mediterranean [15, 68, 69]: gastrointestinal
manifestations occur in one-third of Japanese patients, while
in Turkey and Israel, the prevalence is about 0–5% [2,
49]. There is no signiﬁcant diﬀerence in the frequency of
gastrointestinal involvement between male and female [2,
11].
Gastrointestinal system manifestations can occur
throughhout the gastrointestinal tract, from the esophagus
to the anus. The ulcers are most commonly found in the
terminal ileum, followed by the caecum and other parts of
the colon [70]. The ileocaecal ulcers have a distinct tendency
to perforate. They may lead to symptoms of abdominal pain,
diarrhea, or constipation and proctorrhagia as well as the
acute abdomen, which can be caused by perforation of ulcers
[31, 71].
Gastritis, peptic ulcers, abdominal pain, dyspepsia, vom-
iting,anddiarrheamaybeduetostomachandsmallintestine
ulcers, while dysphagia, retrosternal pain, and hematemesis
are due to esophageal ulcers.
The diﬀerential diagnosis of BD from inﬂammatory
bowel disease is sometimes diﬃcult and challenging. The
main diﬀerential diagnosis of lower intestinal lesions is with
Crohn’s disease. Both diseases have the same ulceration. It
was shown that ulcers in BD were usually round or oval,
while in Crohn’s disease, they were essentially longitudinal.
If there is a longitudinal ulcer in BD, the disease has
focal distribution, otherwise if distribution is segmental or
diﬀuse, it is Crohn’s disease [31, 72]. In addition to ulcers,
granuloma formation in intestinal lesions suggests Crohn’s
disease, which is not seen in BD [73]. The association of RAS
with coeliac disease is well established. It has been suggested
that up to 5% of patients with RAS have gluten-sensitive
enteropathy [16, 74].
3.4. Articular Involvement. Articular involvement is seen
in approximately 30–70% of BD and may be the ﬁrst
manifestation of the disease in about 16.5% of them [2]. It
aﬀects commonly knees, ankles, wrists, and elbows [2, 11].
Articular involvement is observed in the form of arthralgia,
arthritis, and synovitis. Arthralgia is mainly of inﬂammatory
type. Joint disease, which can be symmetrical, usually mono-
or oligoarticular and heals in few weeks, but may take several
weeks or months to heal. It is usually transient, nonerosive,
and nondeforming. Chronic or polyarticular arthritis and
osteonecrosis can be seen occasionally. Ankylosing spondyli-
tis is not seen in BD for some authors, while for others it is
relatedtoBD[3,31].Sacroiliitisandinvolvementofthespine
are not among the common manifestations of BD, which can
serve as diﬀerential diagnosis for Reiter’s syndrome.
Articularinvolvementmaybeconfusedwithseronegative
arthropathies, rheumatoid arthritis, and psoriatic arthritis.
When the joint manifestations are acute and transient, the
disease resembles to rheumatic fever. Chronic and polyartic-
ularform,whichisexceptional,mimicsrheumatoidarthritis.
However, the articular changes of rheumatoid arthritis are
destructive in character [75]. Synovial ﬂuid analysis and
synovial biopsies may help diagnosis by determining the
cell type which may diﬀerentiate arthritis of BD from
the rheumatoid arthritis. Serological abnormalities are seen
in inﬂammatory arthropathies. Seronegative arthropathies
have mainly psoriasiform skin lesions, aortic insuﬃciency,
frequent axial involvement and peripheral enthesopathies,
and sacroiliitis.
3.5. Vascular. B Di sas y s t e m i cv a s c u l i t i sa ﬀecting virtually
all types and sizes of vessels. The prevalence of vascular
involvement is about 1.8–33% and was found higher in male
patients than females [2, 4, 31].
Venous system involvement is more common than arte-
rial system involvement. Venous involvement results in both
superﬁcial thrombophlebitis and deep venous thrombosis.
Venous thrombosis aﬀects extremities, mainly lower limbs.
Large vein thrombosis is less frequent than deep vein
thrombosis of limbs. It involves mainly superior and inferior
vena cava, but may also aﬀect mesenteric, portal, hepatic,
splenic, renal, dural sinus, jugular, subclavian axillary, and
iliac veins. Occlusion of suprahepatic veins, which is rare,
causes a Budd-Chiari syndrome, leading to mortality [76,
77]. In addition to Budd-Chiari syndrome, thromboses of
the superior and inferior vena cava and of dural sinuses
are associated with a poor prognosis [15, 77, 78]. Hughes-
Stovin syndrome should be diﬀerentiated from BD in which
deep venous thrombosis, often involving the vena cava, is
seen accompanied by single or multiple pulmonary arterial
aneurysms.
Arterial lesions are less frequently observed in Behc ¸etpa-
tients. Arterial involvement includes thrombosis, aneurysms,
and pulse weakness and aﬀects pulmonary, iliac, popliteal,
femoral, and carotid arteries. Pulmonary arterial aneurysms,Pathology Research International 7
which occur in 1% of patients, have a high mortality rate.
The main symptom is haemoptysis, and these patients
usually have associated thrombophlebitis and deep venous
thrombosis [3].
The arterial involvement in BD resembles those of
Takayasu’s arteritis, including aneurysm formation and
arterial occlusion. It is suggested that arterial involvement
of BD may result from neutrophilic vasculitis, which targets
the vasa vasorum [79]. Accordingly, on histopathological
studies, it was demonstrated that the number of vasa
vasorum inﬁltrated with neutrophils and lymphocytes was
signiﬁcantly increased in vasculo-Behc ¸et’s disease compared
with that in Takayasu’s arteritis and other inﬂammatory
aneurysms [79].
3.6. Pulmonary Involvement. Pulmonary involvement is rare
in BD (0.7–7%) [2]. It has a higher frequency in males than
females [2, 11].
Pulmonary manifestations have diﬀerent etiology: vas-
culitis, embolism, ﬁbrosis, pleurisy, and infection. The man-
ifestations are mainly related to vasculitis of the pulmonary
arteries, veins, and septal capillaries. Pulmonary vascular
involvement can lead to aneurysm formation (aortic or
pulmonaryarteryaneurysm),thromboticocclusion,(mainly
in the vena cava), haemorrhage, pleural eﬀusion, pulmonary
infarct, and focal or diﬀuse pulmonary ﬁbrosis. Aneurysms
are more common than thrombosis and tend to be multiple
[31]. Although venous system involvement is more common
than arterial system involvement, rupture of an arterial
aneurysm is a signiﬁcant cause of mortality in BD. The most
common and predominant symptom of pulmonary arterial
aneurysm is haemoptysis.
It must be known that detection of a pulmonary an-
eurysminthesettingofavasculiticillnessishighlysuggestive
of BD, which is found rarely in other forms of vasculitis
[17, 80].
3.7. Cardiac Involvement. Cardiac involvement is uncom-
mon in BD. Multiple case reports can be found in the
literature on cardiac manifestations, describing every form
of cardiac involvement such as myocarditis, valvular lesions,
pericarditis, ventricular aneurysms, intracardiac thrombosis,
coronary vasculitis, and many others [15, 81]. Currently, it
was shown that atherosclerosis is probably not increased in
Behc ¸et’s disease, unlike rheumatoid arthritis and systemic
lupus erythematosus [2, 3, 82].
3.8. Genitourinary System Involvement. Renal involvement is
not frequent in BD and is usually transient. Sometimes they
may become chronic. Hematuria, proteinuria, leukocyturia,
and rarely cast may be seen in the patients with renal
involvement of BD. Urethritis is not a feature of BD that may
facilitate to distinguish it from Reiter’s syndrome [17, 31].
Orchitis and epididymitis can also occur in patients with
BD[31].Theyhavealowtendencyforrecurrence.Theattack
of epididymitis may be a painful or a painless swelling, but
the attack of orchitis, which aﬀects both testicles, is painful.
A t t a c k sl a s tf o rf e wd a y so rw e e k s .
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